Afatinib

LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung...


EGFR belongs to the ErbB family of transmembrane tyrosine kinase receptors ( ErbB comprises ErbB1/EGFR/HER1, ErbB2/HER2/NEU, ErbB3/HER3, and ErbB4/HER4 )....


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized...


Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective / non-randomized studies, however, this...


Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3...


New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin...


Results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...